Up to 18% of U.S. participants in ENVISION — a Phase 4 post-marketing study of Aduhelm (aducanumab) in early…
Articles by Steve Bryson, PhD
Treatment with Aduhelm (aducanumab) showed a significant correlation with lower blood levels of p-tau181, a disease biomarker, and lesser cognitive…
Detailed molecular signatures in three mouse models of Alzheimer’s disease at different disease stages allowed for identification of four…
Hyperbaric oxygen therapy (HBOT) — treatment in which patients are given pure oxygen — prevented the biological processes responsible for…
AADvac1, an investigational vaccine targeting abnormal tau protein, a hallmark of Alzheimer’s disease, was found to be safe…
The investigational therapy gantenerumab significantly lowered levels of established biomarkers in a rare, inherited form of early-onset Alzheimer’s…
Following a positive review of preliminary data, an independent board recommended the Phase 2b/3Â study investigating…
Racial discrimination is a barrier to care in Alzheimer’s disease and dementia, according…
Cortexyme’s ongoing Phase 2/3 GAIN clinical trial, which is evaluating…
BAN2401, an experimental treatment for Alzheimer’s disease (AD), will be…